Perennial Investment Advisors LLC Purchases 8,195 Shares of Pfizer Inc. (NYSE:PFE)

Perennial Investment Advisors LLC grew its position in Pfizer Inc. (NYSE:PFE) by 49.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 24,920 shares of the biopharmaceutical company’s stock after purchasing an additional 8,195 shares during the period. Perennial Investment Advisors LLC’s holdings in Pfizer were worth $661,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the company. PSI Advisors LLC lifted its position in Pfizer by 1.4% during the 4th quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company’s stock worth $738,000 after buying an additional 385 shares in the last quarter. Patriot Financial Group Insurance Agency LLC raised its holdings in Pfizer by 1.0% during the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company’s stock worth $1,027,000 after acquiring an additional 391 shares in the last quarter. D Orazio & Associates Inc. boosted its position in Pfizer by 5.5% during the fourth quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company’s stock valued at $200,000 after purchasing an additional 391 shares during the last quarter. Lipe & Dalton boosted its position in Pfizer by 17.7% during the fourth quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 400 shares during the last quarter. Finally, Oliver Luxxe Assets LLC grew its stake in Pfizer by 2.2% in the fourth quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company’s stock valued at $499,000 after purchasing an additional 401 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently commented on PFE shares. Bank of America reissued a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. UBS Group decreased their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Truist Financial dropped their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Finally, Citigroup reiterated a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, six have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the firm’s stock in a transaction on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.06% of the stock is owned by insiders.

Pfizer Price Performance

Pfizer stock opened at $22.99 on Friday. The company has a market capitalization of $130.39 billion, a price-to-earnings ratio of 16.31, a PEG ratio of 0.64 and a beta of 0.67. The stock’s 50 day moving average is $25.87 and its 200-day moving average is $26.74. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12 month low of $22.95 and a 12 month high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same period in the prior year, the firm posted $0.10 EPS. The company’s revenue for the quarter was up 24.7% on a year-over-year basis. Equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.